Results 151 to 160 of about 4,565 (192)

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database. [PDF]

Sci Prog
Zhao W, Jin X, Li Y, Peng H, Jiang J.
europepmc   +1 more source

Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes. [PDF]

JTO Clin Res Rep
Singhal S, Hui C, Neal JW, Nagpal S, Roy M, Das M, Ramchandran K, Pollom E, Selvaggi G, Wakelee HA, Myall NJ.   +10 more
europepmc   +1 more source

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer. [PDF]

Cell Death Dis
Martín F, Alcon C, Marín E, Morales-Sánchez P, Manzano-Muñoz A, Díaz S, García M, Samitier J, Lu A, Villanueva A, Reguart N, Teixido C, Montero J.   +12 more
europepmc   +1 more source

Small-Molecule Drugs in Pediatric Neuro-Oncology. [PDF]

Curr Oncol
Vairy S, Michaiel G.
europepmc   +1 more source

Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future. [PDF]

J Enzyme Inhib Med Chem
Zhang D, Zhao J, Yang Y, Dai Q, Zhang N, Mi Z, Hu Q, Liu X.   +7 more
europepmc   +1 more source

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. [PDF]

Med Sci (Basel)
Shalata W, Naamneh R, Najjar W, Abu Amna M, Asla M, Agbarya A, Brenner R, Abu Jama A, Abu Yasin N, Abu Juda M, Abu Zeid EED, Rouvinov K, Yakobson A.   +12 more
europepmc   +1 more source

Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors. [PDF]

Pharm Res
Takei Y, Kuroiwa H, Arai C, Doi Y, Semba K.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Brigatinib-induced tuberculosis reactivation: A case report

Current Problems in Cancer, 2021
Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor ...
Volkan Keş, Osman Sütcüoğlu, Fatih Gürler, Ozan Yazıcı, Ahmet Özet   +4 more
openaire   +3 more sources

Brigatinib-associated autoimmune hepatitis: A case report

Journal of Oncology Pharmacy Practice, 2023
Introduction Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a wide variety of ALK mutations and ROS1 rearrangements. While pancreatic enzyme elevations due to brigatinib are well known, we wanted to present a case that caused liver toxicity.
Mahmut Buyuksimsek, Ali Ogul, Abdullah Evren Yetisir, Berna Bozkurt Duman, Mert Tohumcuoglu, Timucin Cil, Tolga Koseci, Mehmet Mutlu Kidi, Hilmi Erdem Sumbul   +8 more
openaire   +2 more sources

Brigatinib

Reactions Weekly, 2019
Wörmann, Bernhard, Griesinger, Frank, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Eberhardt, Wilfried E. E., Waller, Cornelius, Huber, R. M., Sebastian, Martin, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +8 more
  +5 more sources